logo
logo
DXCM stock ticker logo

DexCom, Inc.

NASDAQ•DXCM
CEO: Mr. Kevin Ronald Sayer
セクター: Healthcare
業種: Medical - Devices
上場日: 2005-04-14
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
連絡先情報
6340 Sequence Drive, San Diego, CA, 92121, United States
858-200-0200
www.dexcom.com
時価総額
$26.56B
PER (TTM)
31.5
27.7
配当利回り
--
52週高値
$89.98
52週安値
$54.11
52週レンジ
39%
順位44Top 53.8%
3.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$1.26B+0.00%
直近4四半期の推移

EPS

$0.69+0.00%
直近4四半期の推移

フリーCF

$192.10M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Growth Strong Revenue reached $4.66B USD, up 16% from $4.03B in 2024, driven by volume.
Operating Income Surged Operating income surged 52.0% to $911.8M USD, showing strong operating leverage.
Cash Flow Increased Operating cash flow totaled $1.44B USD, increasing 46% from $989.5M in 2024.
Customer Base Expansion Added 600,000 to 700,000 net customers in 2025, excluding Stelo biosensor users.

リスク要因

Manufacturing Compliance Issues Received FDA warning letter March 2025 regarding manufacturing quality system non-conformities.
Gross Margin Pressure Gross profit margin decreased in 2025 due to supply inefficiencies and total replacement costs.
Medicare Reimbursement Uncertainty Medicare competitive bidding extension expected to lower reimbursement rates beginning in 2028.
Pricing Headwinds Persist Pricing pressure from payors offset increased sales volume growth during the fiscal year.

見通し

Future CGM Development Plan future CGM generations focused on improved performance and intelligent insulin administration.
Manufacturing Capacity Scaling Building new manufacturing facility in Athenry, Ireland to scale capacity for future demand.
Partnerships for Integration Continue supporting partnerships integrating CGM technology into insulin delivery systems.
New Market Opportunities Exploring offerings for pre-diabetes, obese, pregnant, and hospital patient populations.

同業比較

売上高 (TTM)

TEVA stock ticker logoTEVA
$17.26B
+4.3%
LH stock ticker logoLH
$13.95B
+7.2%
SNN stock ticker logoSNN
$11.61B
+9.9%

粗利益率 (最新四半期)

BNTX stock ticker logoBNTX
90.2%
+4.6pp
BIIB stock ticker logoBIIB
78.2%
-9.8pp
PODD stock ticker logoPODD
72.5%
+2.9pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
TEVA$35.61B25.920.1%42.7%
NTRA$27.63B-130.1-15.3%8.5%
BIIB$27.13B21.07.3%23.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
6.7%
安定成長
4四半期純利益CAGR
36.4%
収益性の大幅な改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月29日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし